Publication Name	World Journal of Diabetes
Manuscript ID	82346
Country	Croatia

Received	2022-12-15 16:26
Peer-Review Started	2022-12-15 16:28
To Make the First Decision
Return for Revision	2023-01-20 01:19
Revised	2023-01-22 19:47
Second Decision	2023-03-20 03:15
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2023-03-20 09:32
Articles in Press	2023-03-20 09:32
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2023-04-06 09:03
Publish the Manuscript Online	2023-04-12 11:34

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Minireviews
Article Title	Semaglutide-eye-catching results
Manuscript Source	Invited Manuscript
All Author List	Maja Cigrovski Berkovic and Felice Strollo
Funding Agency and Grant Number
Corresponding Author	Maja Cigrovski Berkovic, MD, PhD, Adjunct Associate Professor, Faculty of Kinesiology, University of Zagreb, 15 Horvacanski Zavoj, Zagreb 10000, Croatia. maja.cigrovskiberkovic@gmail.com
Key Words	Glucagon-like peptide-1 receptor agonists; Semaglutide; Diabetic retinopathy; Microvascular complications; Cardiovascular benefit; Rehabilitation
Core Tip	Glucagon-like peptide-1 receptor agonists (GLP-1RAs) benefit patients with type 2 diabetes mellitus in terms of glucose management, weight control, oxidative damage, and prevention of adverse renal and cardiovascular events without increasing the of risk of hypoglycemia. After reviewing the literature to investigate upon such a clinically relevant issue, the authors found that: Semaglutide per se seems to cause no direct damage to the retina, and the reported adverse effects might even be ascribed to a bias in the trial design. Special attention to the retinopathy status should be paid at present when using semaglutide in older patients with longstanding diabetes.
Publish Date	2023-04-12 11:34
Citation	Cigrovski Berkovic M, Strollo F. Semaglutide-eye-catching results. World J Diabetes 2023; 14(4): 424-434
URL	https://www.wjgnet.com/1948-9358/full/v14/i4/424.htm
DOI	https://dx.doi.org/10.4239/wjd.v14.i4.424

Full Article (PDF)	WJD-14-424.pdf
Full Article (Word)	WJD-14-424.docx
Manuscript File	82346_Auto_Edited-JLW.docx
Answering Reviewers	82346-Answering reviewers.pdf
Audio Core Tip	82346-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	82346-Conflict-of-interest statement.pdf
Copyright License Agreement	82346-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	82346-Language certificate.pdf
Peer-review Report	82346-Peer-review(s).pdf
Scientific Misconduct Check	82346-Bing-Chen YL-2.png
Scientific Editor Work List	82346-Scientific editor work list.pdf
CrossCheck Report	82346-CrossCheck report.pdf